Government of Maryland Report issue

Government Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2020
NCT04235049
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Baltimore City Health Department | Maryland Department of Public Safety and Correctional Services | Maryland State Tobacco Quitline | State of Maryland

Active Ingredients

Drugs in Phase 4 Trials (2)

glecaprevir (Mavyret) (1 trial)

pibrentasvir (Mavyret) (1 trial)

Drugs in Phase 3 Trials (1)

buprenorphine (1 trial)

Drugs in Phase 2 Trials (1)

COVID-19 convalescent plasma (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis C (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 4